Center for Immunotherapy and Cell-Based Technologies

Novosibirsk — Kaliningrad — Moscow — Irkutsk
Main

Lung cancer

Xenovaccinotherapy for cancer

http://www.medicalnewstoday.com/rss/cancer-oncology.xmlhttp://www.medicalnewstoday.com/rss/immune_system.xmlhttp://www.medicalnewstoday.com/rss/multiple_sclerosis.xmlhttp://www.medicalnewstoday.com/rss/stem_cell_research.xml

01.07.2019 Two new studies have uncovered cell mechanisms through which lung cancer uses antioxidants to help it spread to other parts of the body. ...

25.04.2019 Early immune-related molecular changes in airway tissue could potentially predict invasive lung cancer and serve as prevention targets, new study sugg...

09.04.2019 New research in mice and human cells suggests that capsaicin, the compound that gives red peppers its spicy flavor, may slow lung cancer progression....

05.10.2018 Administering the natural red wine anticancer compound resveratrol through the nose could protect against lung cancer, a new mouse study finds....

16.08.2018 In the United States, lung cancer is the second most common cancer and the leading cause of death from cancer. In the first stages, there are often no...

21.05.2018 Researchers destroyed up to 80 percent of lung cancer cells using a type of nanoparticle called 'quantum dots,' which they derived from tea leaves. ...

17.05.2018 Immunotherapies often fail to halt lung cancer's progression. A new study attempts to understand why this is and design a new way to attack it....

09.05.2018 Japanese-based researchers have uncovered a biomarker that may help to diagnose lung cancer much earlier than the current tests can....

19.04.2018 To tell lung cancer from benign tumors, specialists often have to use invasive methods. Yet researchers say that a simple blood test can change that....

19.04.2018 Adding immunotherapy to chemotherapy doubled survival in a trial of metastatic nonsquamous non-small cell lung cancer lacking EGFR and ALK mutations....


Immunotherapy for cancer

An active specific immunotherapy (vaccinotherapy) is a strategy using tumor-associated antigens for including antitumor immune responses. The small structural distinctions of the xenogenic tumor-associated antigens from their human analogues render these antigens highly immunogenic and capable of including immune-mediated, antitumor responses in a patient not only at early, but also at advanced stages of disease, when tumor-derived immunosuppression is significant. Tumor-specfic immunotherapy is able to generate a selective and long-term antitumor effect. Such a therapy has no complications attributable to chemotherapy.

Xenovaccinotherapy for cancer